InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...
City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal ...
Bausch + Lomb acquired Whitecap Biosciences, including its two therapies for potential use in glaucoma and geographic atrophy ...
The Bausch and Lomb Center honors two significant figures in the history of RIT; John J. Bausch and Captain Henry Lomb. With the outbreak of the Civil War in 1861, Henry Lomb enlisted with the ...
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, issued the following ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback